Neurovance appoints ex-Shire lead as VP, clinical development
This article was originally published in Scrip
Executive Summary
Neurovance, a clinical-stage neuroscience-focused company developing centanafadine SR for adult attention-deficit hyperactivity disorder (ADHA), has named Brigitte Robertson vice-president of clinical development. Dr Robertson, a board certified adult, child and adolescent psychiatrist, joins the Cambridge, Massachusetts-based company from Shire, where she was most recently global development strategy team lead. Shire, which is in the process of being acquired by AbbVie, manufactures Vyvanse, the leading ADHD franchise worldwide.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.